Burning Mouth Snydrome
Conditions
Interventions
Group A:Adenosine cobalamin tablets (Chinese medicine quasi-word H13020514), 0.25mg, 3 capsules each time, 3 times a day, orally for 12 weeks.
Group B:Angelica 9 g, raw land 9 g, peach kernel 12 g, safflower 9 g, oyster shell 6 g, red peony 6 g, bupleurum 3 g, licorice 3 g, platycodon 4.5 g, Chuanxiong 4.5 g, Achyranthes 10 g. Decoction with
Group C:combination treatment of adenosine cobalamin tablets and Xuefu Zhuyu for 12 weeks.
Sponsors
Shanghai Ninth People's Hospital, College of Stomatology, Shanghai Jiaotong University School of Medicine
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1) Those who can read and understand the informed consent form and be willing to attending the trial; 2) Male and female aged 18 to 75 years old; 3) Qi deficiency and blood stasis type BMS criteria: BMS was diagnosed according to medical history and clinical symptom, and qi deficiency and blood stasis type were selected by clinical classification, and VAS pain score was assessed; 4) rCBF abnormal criteria: diagnosed by SPECT/CT examination; 5) Those with a constant treatment plan and good compliance.
Exclusion criteria
Exclusion criteria: 1) Those who are diagnosed as other oral mucosal diseases; 2) Those are with unstable, severe, or acutely progressive liver or kidney diseases, such as ALT or AST > 2 times the upper limit of normal, BUN > 1.5 times the upper limit of normal, creatinine > 1.5 times the upper limit of normal; 3) Those who have used antibiotics within 1 month and immunologic preparations within 3 months; 4) Those are with severe and uncontrolled systemic diseases such as hematological diseases, severe neurological damage, ventricular dysfunction with or with a history of congestive heart failure, or any condition that may affects the study treatment and outcome evaluate or fail to ensure completion of the study; 5) Those who are pregnant or nursing; 6) Those who can not tolerate the designed treatment; 7) Expected survival period <3 months; 8) Those with alcoholism, drug dependence, and any subject may be affact the completion of the study judged by the investigator; 9) Those with any clinically significant abnormal results through physical examination or electrocardiogram examination, which may affect the completion of this clinical study and the safety of the participants ; 10) Those who are allergic to medicine used in the treatment.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| rCBF anomaly value; | — |
Secondary
| Measure | Time frame |
|---|---|
| BMS symptom score; | — |
Countries
China
Contacts
Public ContactLan Wu
Shanghai Ninth People's Hospital, College of Stomatology, Shanghai Jiaotong University School of Medicine
Outcome results
None listed